Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.26 - $2.09 $51,372 - $85,213
-40,772 Reduced 5.47%
705,217 $994,000
Q2 2022

Aug 15, 2022

SELL
$0.97 - $3.08 $2.56 Million - $8.12 Million
-2,637,861 Reduced 77.95%
745,989 $895,000
Q1 2022

May 16, 2022

SELL
$2.55 - $5.23 $743,982 - $1.53 Million
-291,758 Reduced 7.94%
3,383,850 $9.81 Million
Q4 2021

Feb 14, 2022

SELL
$4.43 - $8.33 $421,518 - $792,607
-95,151 Reduced 2.52%
3,675,608 $16.3 Million
Q3 2021

Nov 15, 2021

SELL
$6.07 - $9.89 $2.01 Million - $3.28 Million
-331,758 Reduced 8.09%
3,770,759 $27.5 Million
Q2 2021

Aug 16, 2021

SELL
$9.76 - $14.15 $848,095 - $1.23 Million
-86,895 Reduced 2.07%
4,102,517 $40.1 Million
Q1 2021

May 17, 2021

SELL
$7.66 - $13.38 $220,562 - $385,263
-28,794 Reduced 0.68%
4,189,412 $49.6 Million
Q4 2020

Feb 16, 2021

SELL
$6.1 - $7.94 $287,163 - $373,783
-47,076 Reduced 1.1%
4,218,206 $33.1 Million
Q3 2020

Nov 16, 2020

SELL
$6.52 - $8.94 $446,104 - $611,683
-68,421 Reduced 1.58%
4,265,282 $29 Million
Q2 2020

Aug 14, 2020

BUY
$6.18 - $10.76 $1.69 Million - $2.95 Million
273,914 Added 6.75%
4,333,703 $32.5 Million
Q1 2020

May 15, 2020

SELL
$6.03 - $15.24 $263,125 - $665,012
-43,636 Reduced 1.06%
4,059,789 $25.5 Million
Q4 2019

Feb 14, 2020

SELL
$9.07 - $15.84 $392,277 - $685,080
-43,250 Reduced 1.04%
4,103,425 $62.2 Million
Q3 2019

Nov 14, 2019

SELL
$9.63 - $14.0 $253,394 - $368,382
-26,313 Reduced 0.63%
4,146,675 $42.5 Million
Q2 2019

Aug 13, 2019

BUY
$13.4 - $17.67 $31.4 Million - $41.4 Million
2,343,760 Added 128.13%
4,172,988 $61.6 Million
Q1 2019

May 17, 2019

BUY
$5.7 - $19.7 $10.4 Million - $36 Million
1,829,228 New
1,829,228 $30.1 Million

Others Institutions Holding MGTA

About Magenta Therapeutics, Inc.


  • Ticker MGTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,890,500
  • Description
  • Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...
More about MGTA
Track This Portfolio

Track Gilder Gagnon Howe & CO LLC Portfolio

Follow Gilder Gagnon Howe & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.